Andere Sprachen BeiGene, Ltd.

Aktien

A1437N

US07725L1026

BGNE

Biotechnologie

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 12.12.2024			% 5 Tage	% 1. Jan.
180,27 ^USD	-2,23 %		-9,45 %	-0,05 %

11.12.	BeiGene sichert sich 400 Millionen Dollar Kredit von der China Merchants Bank	MT
10.12.	Asiatische Aktien im US-Handel als American Depositary Receipts im Dienstagshandel deutlich niedriger	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor	01:31
Beigene Insider Sold Shares Worth $7,805,106, According to a Recent SEC Filing	12.12.
BeiGene Secures $400 Million Facility from China Merchants Bank	11.12.
BeiGene renforce son leadership dans la LLC à l’ASH 2024 avec de nouvelles données issues de sa franchise hématologique comprenant BRUKINSA® et de nouveaux actifs en cours de développement	11.12.
BeiGene avanza en el liderazgo en el campo de la LLC en ASH 2024 con nuevos datos de su franquicia de hematología, incluidos BRUKINSA® y nuevos activos en desarrollo	11.12.
Asian Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday Trading	10.12.
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets	10.12.
BeiGene, Ltd. Advances Leadership in CLL at ASH 2024 with New Data from Its Hematology Franchise Including BRUKINSA and Novel Pipeline Assets	10.12.
Jazz Pharmaceuticals Announces Ziihera Investor Webcast on December 11, 2024	05.12.
BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL	04.12.
BeiGene, Ltd. and CLL Society Partner to Advance Test Before Treat? Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL	04.12.
BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024	02.12.
BeiGene Insider Sold Shares Worth $9,190,570, According to a Recent SEC Filing	02.12.
Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading	29.11.
Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List	29.11.
Hong Kong Stocks End Week in Green; Mokingran Jewellery Gains 8% in Debut	29.11.
BeiGene's Four Drugs Included in China's Medical Insurance Catalog; Shares Jump 5%	29.11.
European Commission Approves BeiGene's TEVIMBRA for First-Line Treatment of Advanced, Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer	28.11.
La Commission européenne approuve TEVIMBRA de BeiGene pour le traitement de première intention du carcinome épidermoïde de l'œsophage avancé/métastatique et du cancer de la jonction gastrique ou gastro-œsophagienne	27.11.
BeiGene Shares Up on EU Approval for Gastric, Esophageal Cancer Treatment	27.11.
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday	27.11.
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Ahead of Crucial Inflation Data	27.11.
BeiGene's Tevimbra Gets Approval From European Commission as Treatment for Cancer Patients	27.11.
BeiGene's Gastric, Esophageal Cancer Treatment Gets EU Approval	27.11.
European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer	27.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen BeiGene, Ltd.

Aktien

A1437N

US07725L1026

BGNE

Biotechnologie

Andere Sprachen

Filter